Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

BACKGROUND AND OBJECTIVE: Brensocatib is an investigational, first-in-class, selective, and reversible dipeptidyl peptidase 1 inhibitor that blocks activation of neutrophil serine proteases (NSPs). The NSPs neutrophil elastase, cathepsin G, and proteinase 3 are believed to be central to the pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalmers, James D., Usansky, Helen, Rubino, Christopher M., Teper, Ariel, Fernandez, Carlos, Zou, Jun, Mange, Kevin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553789/
https://www.ncbi.nlm.nih.gov/pubmed/35976570
http://dx.doi.org/10.1007/s40262-022-01147-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553789/
https://www.ncbi.nlm.nih.gov/pubmed/35976570
http://dx.doi.org/10.1007/s40262-022-01147-w

Ejemplares similares